Duloxetine Capsule, Delayed Release
Product Images NDC 50090-7897

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-7897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

The image shows the packaging label for Duloxetine 60 mg delayed-release capsules. The label features the product name and strength prominently, a decorative flower-like pattern with various black and grey circles, and the manufacturer name, A-S Medication Solutions. Capsule form and oral route are implied by the presentation and typical label layout.*

FDA Label Image

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)

Chemical structure of duloxetine hydrochloride showing its molecular framework with a naphthalene group and a thiophene ring connected via an ether and amine functional groups.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)

A Kaplan-Meier estimator graph showing the proportion of patients with relapse over time (in days) from randomization. The chart compares two treatment groups: Placebo and Duloxetine. The x-axis represents time up to 250 days, and the y-axis represents the proportion of patients with relapse, ranging from 0 to 1.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)

A Kaplan-Meier curve showing the proportion of patients with relapse over time in days after randomization, comparing Duloxetine and placebo treatment groups. The graph illustrates relapse rates for Duloxetine and placebo over approximately 250 days.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo groups, showing differing patient improvement percentages across various pain reduction levels.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline comparing Duloxetine 60 mg taken twice daily (BID), Duloxetine 60 mg taken once daily (QD), and placebo. The graph illustrates trends of patient improvement with Duloxetine dosages providing higher improvement percentages than placebo.*

FDA Label Image

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. The y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (solid line), Duloxetine 60 mg once daily (open circle), and placebo, showing trends of patient improvement in pain across a range of percent improvement values.*

FDA Label Image

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)

A line graph displaying the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The graph compares Duloxetine 60 mg once daily to placebo, showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. Duloxetine treatment shows higher pain relief percentages across most pain improvement levels.*

FDA Label Image

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The vertical axis shows percentage of patients improved, and the horizontal axis shows percent improvement in pain from >0 to 100. Duloxetine consistently shows higher percentages of patient improvement across the pain improvement scale compared to placebo.*

FDA Label Image

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines depict the improvement trends for Duloxetine and placebo groups.*

FDA Label Image

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows two lines plotting patient improvement percentages along varying levels of pain improvement, with Duloxetine consistently showing higher percentages than placebo across the range.*

FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Duloxetine 60 mg delayed-release capsules packaging card, featuring multiple gray capsules arranged in a flower-like pattern on a white background. The label does not show additional text or manufacturer branding. The capsules have a smooth, solid color surface.*

FDA Label Image

Label Image (Lbl500907897)

Duloxetine USP delayed-release capsules, 60 mg strength, in a bottle label form. The label indicates each capsule contains 60 mg of duloxetine hydrochloride equivalent. The package contains 90 capsules and is labeled for oral use, stored at 77 degrees Fahrenheit. It is manufactured or labeled by A-S Medication Solutions, Libertyville, IL, with product number S6492-0 and NDC 50090-7897-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.